Bank of America just raised its EUR/USD forecast
David Altshuler, Executive Vice President and Chief Scientific Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a prominent biotechnology company with a market capitalization of $122.8 billion, recently sold shares of the company’s stock valued at $610,560. According to InvestingPro data, Vertex maintains a strong financial health score and has delivered an impressive 17.83% return year-to-date. The transaction, carried out on February 27, 2025, involved the sale of 1,272 shares at a price of $480 each. This sale was part of a pre-established trading plan under Rule 10b5-1, which Altshuler entered into on August 8, 2024.
Following the sale, Altshuler’s direct ownership of Vertex Pharmaceuticals stock stands at 32,974 shares. Prior to this transaction, on February 26, 2025, Altshuler disposed of 5,954 shares at a price of $479.61 each, as part of a separate transaction.
In other recent news, Vertex, Inc. reported its fourth-quarter results, which were in line with expectations, but issued a weaker-than-expected forecast for the first quarter of 2025. The company announced adjusted earnings per share of $0.15, slightly surpassing analyst expectations of $0.14. Revenue for the quarter reached $178.5 million, which was slightly above the consensus estimate of $176.9 million and represented a 15.2% increase year-over-year. However, the company’s guidance for Q1 2025 projected revenue between $175 million and $178 million, falling short of analysts’ projections of $180.3 million.
For the full year 2025, Vertex expects revenue to be between $760 million and $768 million, aligning with the consensus estimate of $764 million. The company highlighted its cloud revenues, which grew 27% year-over-year to $76.9 million, and an Annual Recurring Revenue increase of 17.7% year-over-year to $603.1 million, boosted by recent acquisitions. Vertex plans to invest an additional $14-16 million in research and development for AI initiatives and emerging technologies, as noted by Chief Financial Officer John Schwab. Despite these positive long-term projections, the market reacted negatively to the first-quarter guidance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.